On October 16, 2024 Pillar Biosciences, Inc., the leader in Decision Medicine, reported an expansion of their existing partnership with Illumina, through which a broader portfolio of Pillar’s oncoReveal NGS panels will now be offered directly by Illumina (Press release, Pillar Biosciences, OCT 16, 2024, View Source [SID1234647235]). Several of Pillar’s oncology panels will be available as part of the validated libraries on the MiSeq i100 Series sequencing platform, which launched last week.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The additional research-use-only (RUO) oncology NGS panels manufactured by Pillar Biosciences and available directly through Illumina will include:

Liquid Biopsy Tumor Profiling:

oncoReveal Core LBx
oncoReveal Essential LBx
oncoReveal Fusion LBx
Solid Tumor Profiling:

oncoReveal Multicancer RNA Fusion (18-Driver gene RNA panel)
oncoReveal Solid Tumor v2 (48-gene DNA panel)
These panels are enabled on the MiSeq and NextSeq 550 Systems. Pillar Biosciences panels that are enabled on the newly launched Illumina MiSeq i100 Series include:

oncoReveal Essential MPN
oncoReveal Myeloid
oncoReveal Multi-Cancer with CNV and Fusion Panel
oncoReveal BRCA1 & BRCA2 plus CNV Panel
"As part of Illumina’s commitment to address our customers’ total workflow, we are pleased to bring more oncology assays from Pillar Biosciences into our product lineup, including the new MiSeq i100 Series," said Angela Ryan, Vice President, Product Management at Illumina.

"We are excited about the commercial progress generated through our collaboration with Illumina over the past 18 months. By expanding their oncology offering with rapid, high-quality targeted genomic content we can ensure more customers have a full suite of NGS solutions to fulfill their genomic profiling needs," said Dan Harma, Chief Commercial Officer at Pillar Biosciences. "Pillar and Illumina’s NGS solutions are complementary and have very specific technical benefits. These can be utilized together efficiently. We look forward to working together to better enable our customers and further driving localized NGS services."

On October 16, 2024 Medigene AG (Medigene or the "Company", FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, reported that it will present at the 16th Annual Protein & Antibody Engineering Summit (PEGS) to be held from November 5-7, 2024 in Barcelona as well as at the Cell 2024 conference by Oxford Global from November 6-8, 2024 in London (Press release, MediGene, OCT 16, 2024, View Source [SID1234647234]). In addition, two posters will be presented at the 39th Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) from November 6-10, 2024, in Houston, TX, USA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral presentation

PEGS 2024
View Source
Location: Montjuic Palau de Congressos- Fira Barcelona, Spain
Date and time: Thursday, November 7, 2024, 8:25 am local time
Presenter: Kanuj Mishra, PhD, Team Lead & Lab Head, Innovation
Session: Next-Generation Immunotherapies
Title: Seamless Integration of a Universal Epitope into Recombinant TCRs for Tagging and Tracking of TCR-T Cells Expressing 3S TCRs

The presentation will highlight the Company’s latest technology, UniTope & TraCR, an innovative combination of universal TCR tagging and tracking. This advanced system is engineered to greatly improve the precision and efficiency of T cell receptor identification and monitoring, providing benefits for immunotherapy research and clinical applications.

Cell 2024 by Oxford Global
View Source

Panel Discussion
Location: Novotel London West, London, UK
Date/time: Wednesday, November 6, 2024, 3 p.m. local time
Presenter: Kirsty Crame, MD, Vice President, Clinical Strategy and Development
Session: Exploring Autologous Vs. Allogenic Therapies

Keynote Address
Location: Novotel London West, London, UK
Date/time: Thursday, November 7, 2024, 9.30 a.m. local time
Presenter: Kirsty Crame, MD, Vice President, Clinical Strategy and Development
Session: CGT Development
Title: Making The Ordinary Extraordinary: MDG1015 A Clinic Ready 3rd Generation TCR-T Therapy

Oral presentation
Location: Novotel London West, London, UK
Date/time: Friday, November 8, 2024, 2.20 p.m. local time
Presenter: Prof. Dolores Schendel, CSO
Session: iPSCs and stem cell therapy development
Title: TCR-T Platform for Solid Tumors

SITC 2024
View Source
Location: George R. Brown Convention Center in Houston, TX
Date and time: November 6-10, 2024 in Houston, TX

Details on the poster presentation are as follows:
Abstract and Title: " UniTope & TraCR – A universal tagging and tracking system for TCR-T cells directly integrated in recombinant TCR."
Authors: Kanuj Mishra, Justyna Ogonek, Dolores Schendel, Barbara Loesch
Abstract number: 20
Date/time: Saturday, November 9, 2024, George R. Brown Convention Center – Level 1 -Exhibit Halls AB, poster reception from 7:10-8.30 p.m.
Presenter: Barbara Loesch, PhD, Head of Technology and Innovation Department
Session: Biomarkers, Immune Monitoring and Novel Technologies

Abstract and Title: "The IFN-γ Biosensor – A universal tool for IFN-γ detection in cellular co-culture assays."
Authors: Barbara Loesch, Kanuj Mishra, Justyna Ogonek, Dolores Schendel
Abstract number: 21
Date/time: Friday, November 8, 2024, George R. Brown Convention Center – Level 1 -Exhibit Halls AB, poster reception from 5:30-7 p.m.
Presenter: Barbara Loesch, PhD, Head of Technology and Innovation Department
Session: Biomarkers, Immune Monitoring and Novel Technologies

On October 16, 2024 Theriva Biologics (NYSE American: TOVX), ("Theriva" or the "Company"), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, reported that the European Commission has adopted the European Medicines Agency (EMA) recommendation to grant orphan medicinal product designation to lead clinical candidate VCN-01, Theriva’s systemic, selective, stroma-degrading oncolytic adenovirus, for the treatment of retinoblastoma (Press release, Theriva Biologics, OCT 16, 2024, View Source [SID1234647233]). The United States Food and Drug Administration (FDA) has previously granted orphan drug designation and rare pediatric disease designation to VCN-01 for the treatment of retinoblastoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very pleased with the European Commission’s grant of orphan medicinal product designation to VCN-01, emphasizing the urgent need for new treatment options for retinoblastoma," said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. "We have previously reported encouraging results from an investigator sponsored Phase 1 trial evaluating the safety and activity of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma, and we are working closely with leading physicians and regulatory agencies worldwide to refine our clinical strategy for VCN-01 as an adjunct to chemotherapy in children with this challenging disease."

The EMA recommends orphan designation for products intended to treat, prevent or diagnose a disease that is life-threatening or chronically debilitating and either the prevalence of the condition in the European Union (EU) does not exceed 5 in 10,000 or it is unlikely that marketing of the product would generate sufficient returns to justify the investment needed for its development. Additionally, there should be no authorizable method of diagnosis, prevention or treatment of the condition, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. Orphan designation is designed to provide drug developers with various benefits to support the development of novel therapies, including 10-years of market exclusivity once they receive marketing authorization in the EU, protocol assistance, administrative and procedural assistance, and reduced fees for regulatory activities.

About Retinoblastoma

Retinoblastoma is a tumor that originates in the retina and is the most common type of eye cancer in children. It occurs in approximately 1/14,000 – 1/18,000 live newborns and accounts for 15% of the tumors in the pediatric population < 1 year old. The average age of pediatric patients at diagnosis is 2, and it rarely occurs in children older than 6. In Europe, retinoblastoma has an estimated incidence rate of 1 per 13,844 live births (14.1 per million children under the age of 5) with approximately 300 children diagnosed per year (Stacey et al. 2021). Preserving life and preventing the loss of an eye, blindness and other serious effects of treatment that reduce the patient’s life span or the quality of life, remains a challenge. In addition, children with retinoblastoma have been more likely to lose their eye and die of metastatic disease in low-resource countries.

About VCN-01

VCN-01 is a systemically administered oncolytic adenovirus designed to selectively and aggressively replicate within tumor cells and degrade the tumor stroma that serves as a significant physical and immunosuppressive barrier to cancer treatment. This unique mode-of-action enables VCN-01 to exert multiple antitumor effects by (i) selectively infecting and lysing tumor cells; (ii) enhancing the access and perfusion of co-administered chemotherapy products; and (iii) increasing tumor immunogenicity and exposing the tumor to the patient’s immune system and co-administered immunotherapy products. Systemic administration enables VCN-01 to exert its actions on both the primary tumor and metastases. VCN-01 has been administered to over 140 patients to date in clinical trials of different cancers, including PDAC (in combination with chemotherapy), head and neck squamous cell carcinoma (with an immune checkpoint inhibitor), ovarian cancer (with CAR-T cell therapy), colorectal cancer, and retinoblastoma (by intravitreal injection). More information on these clinical trials is available at Clinicaltrials.gov.

On October 16, 2024 Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, reported that the Company will be providing a corporate update at the upcoming investor conferences on the dates below (Press release, Soligenix, OCT 16, 2024, View Source [SID1234647231]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2024 Maxim Healthcare Virtual Summit, held October 17, 2024. For more information, please refer to the conference website https://m-vest.com/events/healthcare-10152024.

ThinkEquity Conference, held October 30, 2024. For more information, please refer to the conference website View Source

Spartan Capital Investor Conference 2024, held November 4, 2024. For more information, please refer to the conference website View Source
Key members of Soligenix management will hold one-on-one meetings throughout the conferences. If you are unable to attend the conferences and would like to schedule a meeting with management, please contact [email protected].

On October 16, 2024 Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, reported the company will deliver a poster presentation highlighting preclinical data on SKY-1214 at the 36th European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) (Free AACR Whitepaper) Molecular Targets and Cancer Therapeutics Symposium ("EORTC-NCI-AACR") to be held from October 23-25, 2024 in Barcelona, Spain (Press release, Skyhawk Therapeutics, OCT 16, 2024, View Source [SID1234647230]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SKY-1214 is an oral RNA splicing modulator developed through the company’s novel RNA-splicing platform and being developed for difficult to treat multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL). SKY-1214 targets FANCL/FANCI, critical components of the Fanconi anemia DNA damage repair pathway, which MM and NHL cells use to maintain their genome integrity.

Details of the data presentation are as follows:

Title: "Preclinical characterization of SKY-1214, a small molecule splicing

modulator of Fanconi Anemia pathway members for the treatment of

multiple myeloma and non-Hodgkin’s lymphoma"

Session Type: New Drugs

Poster Number: #PB104

Date: Wednesday, 23 October 2024

Location: Exhibition Hall

Presenter: Simone Rauch, PhD, Skyhawk Therapeutics